Clinical Trial Detail

NCT ID NCT02693535
Title TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors American Society of Clinical Oncology
Indications

ovarian cancer

colorectal cancer

bronchus cancer

head and neck cancer

uterine cancer

sarcoma

non-Hodgkin lymphoma

breast cancer

prostate cancer

Advanced Solid Tumor

multiple myeloma

Therapies

Vemurafenib + Cobimetinib

Regorafenib

Vismodegib

Bosutinib

Palbociclib

Cetuximab

Axitinib

Pembrolizumab

Temsirolimus

Dasatinib

Pertuzumab + Trastuzumab

Crizotinib

Sunitinib

Olaparib

Erlotinib

Age Groups: adult

Additional content available in CKB BOOST